证券日报网12月25日讯，联环药业（600513）在接受投资者提问时表示，公司高度重视员工激励与人才 保留，已建立差异化的薪酬体系，研发人员薪酬与项目进展深度挂钩，将研发流程分阶段给予团队相应 奖励，充分调动创新积极性。此外，公司已连续多年为员工调资，让员工切实共享企业发展的成果。公 司将进一步完善激励机制，吸引更多优秀人才投身研发与创新业务。 ...

证券日报网讯 12月25日，富祥药业（300497）发布公告称，截至本公告日，公司尚在有效期内累计担 保总额度为12.29亿元，均为全资子公司及控股子公司担保。公司累计对外担保总额度占公司最近一期 经审计净资产的比例为56.36%，实际已发生的有效对外担保总余额为7.515亿元（含本次新增使用担保 额度），占公司最近一期经审计净资产的比例为34.47%。公司无逾期对外担保，无涉及诉讼的对外担 保及因担保被判决败诉而应承担损失的情形。 ...

| NORTHER THE VEY | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 奥出营业部 | 是否为专场 | | 025-12-25 | 恒瑞医药 | 600276 | 2271.8 61.4 37 | 我們都會隨著點 | 我們都會隨 | Ki | 12月25日，恒瑞医药大宗交易成交37万股，成交额2271.8万元，占当日总成交额的2.33%，成交价61.4 元，较市场收盘价61.4元持平。 ...

从资金流向上来看，当日化学制药板块主力资金净流出10.89亿元，游资资金净流入453.95万元，散户资 金净流入10.84亿元。化学制药板块个股资金流向见下表： 证券之星消息，12月25日化学制药板块较上一交易日上涨0.26%，宏源药业领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301246 | 宏源药业 | 22.40 | 7.74% | 39.25万 | | 8.25 亿 | | 688091 | 上海谊众 | 48.82 | 4.34% | 4.56万 | | 2.20亿 | | 300381 | 溢多利 | 6.72 | 3.70% | 12.15万 | 8094.05万 | | | 002370 | 亚太药业 | 7.54 | 2.86% | - 46.50万 | | 3.48亿 | | 603351 | 威尔药业 | 26.73 ...

Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that the interest payment for its convertible bonds issued on January 4, 2022, will commence on January 5, 2026, due to January 4, 2026, being a non-trading day [1] Group 1 - The interest payment marks the fourth year of interest for the "Borui Convertible Bonds" [1] - The interest accrual period is from January 4, 2025, to January 3, 2026 [1] - The coupon rate for this interest year is set at 1.5% (tax included), resulting in an interest payment of 15 RMB (tax included) for each bond with a face value of 1,000 RMB [1]

Core Viewpoint - TuoXin Pharmaceutical (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd. (referred to as "Jingquan Biotechnology"), has received a Food Production License from the Henan Provincial Market Supervision Administration, allowing for the production of three new food additive products [1] Group 1 - Jingquan Biotechnology's license change includes the addition of production qualifications for three new products: 2-oxopentanoic acid, L-citrulline, and 4-aminobutyric acid (also known as γ-aminobutyric acid) [1]

Group 1 - The company has initiated trial production for its VC project, indicating progress in its development phase [1] - The company acknowledges that it still needs to undergo a capacity ramp-up process, which is a critical step before full-scale production can be achieved [1]

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

截至9月30日，诚达药业股东户数1.27万，较上期减少8.58%；人均流通股8577股，较上期增加36.16%。 2025年1月-9月，诚达药业实现营业收入2.85亿元，同比增长16.95%；归母净利润1677.33万元，同比减 少58.47%。 分红方面，诚达药业A股上市后累计派现1.33亿元。近三年，累计派现8961.79万元。 责任编辑：小浪快报 12月24日，诚达药业跌0.86%，成交额1.51亿元。两融数据显示，当日诚达药业获融资买入额1804.28万 元，融资偿还1214.18万元，融资净买入590.10万元。截至12月24日，诚达药业融资融券余额合计2.63亿 元。 融资方面，诚达药业当日融资买入1804.28万元。当前融资余额2.63亿元，占流通市值的4.11%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，诚达药业12月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年60%分位水平，处于较高位。 资料显示，诚达药业股份有限公司位于浙江省嘉兴市嘉善县惠民街道黄河路36号，成立日期1999年3月 ...

第五届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603538 证券简称：美诺华 公告编号：2025-122 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 宁波美诺华药业股份有限公司（以下简称"公司"）于2025年12月24日以书面、电子邮件等方式向公司全 体董事发出召开第五届董事会第二十二次会议的通知和会议材料。第五届董事会第二十二次会议于2025 年12月24日在公司会议室以现场结合通讯的方式召开。本次会议由姚成志先生主持，会议应出席董事5 名，实际出席董事5名。公司高级管理人员列席了会议。本次会议的召集和召开符合《中华人民共和国 公司法》等有关法律法规及《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 （一）审议通过《关于不向下修正可转换公司债券转股价格的议案》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露媒体同日披露的《关于不向 ...